醫渡科技(02158.HK):擬回購不超10%公司股份
格隆匯10月9日丨醫渡科技(02158.HK)宣佈,公司可根據公司股東於2024年8月30日舉行的股東周年大會上授予的購回授權,於合適的市況下於市場上購回公司已發行普通股。根據股份購回授權,公司獲准購回的股份上限為106,166,266股,佔2024年股東周年大會當日股份總數的10%。
董事會對公司的未來發展前景充滿信心並認可公司價值,為保護投資者合法權益,增強投資者信心,結合公司營運、財務狀況及發展戰略,公司擬進行建議股份購回。建議股份購回將由公司的內部現金資源撥付。董事會相信,公司目前的財務及業務狀況良好,公司有足夠的的財務資源進行建議股份購回,同時為集團業務快速增長維持足夠的營運資金。董事會認為,建議股份購回反映了公司對其業務長期前景的信心。因此,公司認為建議股份購回符合公司及其股東的整體利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.